Denmark’s Novo Nordisk has announced that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen® prefilled devices in Iran.
The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million euros. The production will function in compliance with Good Manufacturing Practices (GMP), which will ensure the quality and reliability of the products.
Ole Moelskov Bech, corporate vice president of Novo Nordisk Business Area Near East, said:
“We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation.
“This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products.”
With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran.
(Source: Novo Nordisk)